A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
Status:
RECRUITING
Trial end date:
2026-06-05
Target enrollment:
Participant gender:
Summary
The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not perceive a sufficient improvement during previous treatment with therapies targeting calcitonin gene-related peptide (CGRP).